Sayak Khawas is a doctoral researcher specializing in respiratory pharmacology and nanomedicine, with a primary focus on nanostructured lipid carriers (NLCs) for the treatment of chronic airway diseases. His doctoral work investigates Iguratimod-loaded NLCs and their therapeutic potential in experimental models of asthma, chronic obstructive pulmonary disease (COPD), and asthma–COPD overlap (ACO). His research employs biochemical, molecular, and immunohistochemical methodologies to examine oxidative stress, inflammatory mediators, and macrophage polarization in the progression of airway pathology. In addition to his thesis research, Khawas has co-authored review articles addressing recent advances in nanomedicine and the applications of bioinks in tissue engineering and regenerative medicine. His academic contributions reflect a commitment to translational science, bridging pharmaceutical innovations with potential clinical applications. He is also engaged in manuscript reviewing and academic writing, with an emphasis on critically identifying gaps in current knowledge and highlighting future directions. His long-term objective is to contribute to the development of nanomedicine-based therapeutic strategies for chronic respiratory diseases through multidisciplinary collaboration and innovation.